IP Library Granted Patent US 8,741,933
Granted Patent B2
US 8,741,933 · App. 13/871,356 · Granted Jun 3, 2014

Modulators of ATP-binding cassette transporters

Inventors: Sara S. Hadida Ruah (La Jolla, CA); Matthew Hamilton (Hackettstown, NJ); Mark Miller (San Diego, CA); Peter D. J. Grootenhuis (San Diego, CA); Brian Bear (Carlsbad, CA); Jason McCartney (Cardiff by the Sea, CA); Jinglan Zhou (San Diego, CA)
Assignee: Vertex Pharmaceuticals Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,741,933
App. No.
13/871,356
Granted
Jun 3, 2014
Kind
B2
Abstract

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Claims (8)

1. A method of treating cystic fibrosis in a patient, wherein the patient has a defective gene that causes a deletion of phenylalanine at position 508 of the cystic fibrosis transmembrane conductance regulator amino acid sequence, said method comprising the step of administering to the patient an effective amount of the compound

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the patient has two copies of the defective gene.

3. A method of treating cystic fibrosis in a patient, wherein the patient has a defective gene that causes a deletion of phenylalanine at position 508 of the cystic fibrosis transmembrane conductance regulator amino acid sequence, said method comprising the step of administering to said patient an effective amount of a composition comprising:

i) the compound:

or a pharmaceutically acceptable salt thereof; and

ii) a pharmaceutically acceptable carrier.

4. The method of claim 3 , wherein the patient has two copies of the defective gene.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
ASSIGNEE CHANGE OF ADDRESS Recorded Feb 3, 2016
From: VERTEX PHARMACEUTICALS INCORPORATED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 037685/0878 →
ASSIGNEE CHANGE OF ADDRESS Recorded Feb 2, 2016
From: VERTEX PHARMACEUTICALS INCORPORATED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 037681/0375 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2013
From: HADIDA RUAH, SARA; HAMILTON, MATTHEW; MILLER, MARK; GROOTENHUIS, PETER; BEAR, BRIAN; MCCARTNEY, JASON; ZHOU, JINGLAN; VANGOOR, FREDRICK
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 031252/0325 →
Continuity (6)
Division 12114935 · May 5, 2008
Continuation PCTUS2006043289 · Nov 8, 2006
Provisional Application 60802458 · May 22, 2006
Provisional Application 60754086 · Dec 27, 2005
Provisional Application 60734506 · Nov 8, 2005
Related Publication 20130237568A1 · Sep 12, 2013